Reevaluation of C-Reactive Protein in Cancer Sera by Radioimmunoassay and Radial Immunodiffusion

Drahovský, D.; Dunzendorfer, U; Ziegenhagen, G.; Drahovsky, M.; Kellen, J

doi:10.1159/000225572

Cited by 22 publications

(10 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3). This result agreed with the presence of CRP in cancer (20 ). The mean P2 value was 1.4 -2.2% of total Tf in alcohol abusers (P Ͼ0.05), whereas it was 0.5-0.6% in abstainers and moderate drinkers, with or without cancer.…”

Section: Review Of All Electropherogramssupporting

confidence: 86%

Analyte Comigrating with Trisialotransferrin during Capillary Zone Electrophoresis of Sera from Patients with Cancer

Ramdani

Nuyens²,

Codden

et al. 2003

Clinical Chemistry

View full text Add to dashboard Cite

Background: Serum concentrations of monoglycosylated isoforms of transferrin are increased by chronic ethanol intake. We investigated transferrin glycosylation in patients with cancer, in which aberrant glycosylation is also induced. Methods: We used a P/ACE 5000 series capillary zone electrophoresis (CZE) apparatus and a CZE carbohydrate-deficient transferrin reagent set to study 200 cancer patients who consumed alcohol moderately and 33 who were alcohol abusers; we then compared these patients with 56 healthy teetotalers, 89 moderate, and 112 excessive alcohol drinkers without known malignancies. Transferrin isoforms were identified by immunosubtraction with anti-human transferrin polyclonal antibody. Results: Seven peaks, P0 -P6, were visualized and completely or partly immunosubtracted when CZE separation was performed at pH 8.5. P0 was present in 95% of alcohol abusers with or without cancer. P3 was significantly higher in cancer patients and was only partly immunosubtracted as trisialotransferrin in all groups. The comigrating analyte was not altered by papain, precipitation by ethanol, or extraction by organic solvents, but was sensitive to acid hydrolysis, suggesting a polysaccharide structure. When isolated at pH 8.25, this analyte was higher in cancer patients. ROC curve analysis identified localized malignant neoplasia at P3 values above 5.8% of total transferrin (sensitivity, 0.78;

show abstract

Section: Review Of All Electropherogramssupporting

confidence: 86%

Analyte Comigrating with Trisialotransferrin during Capillary Zone Electrophoresis of Sera from Patients with Cancer

Ramdani

Nuyens²,

Codden

et al. 2003

Clinical Chemistry

View full text Add to dashboard Cite

show abstract

“…CRP levels correlate with the dissemination of malignant tumours [2]. None of our 8 patients with a history of cancer showed a significant increase of CRP values and ESR possibly because their general condition was relatively unaffected.…”

Section: Discussionmentioning

confidence: 57%

Changes in C-reactive protein and erythrocyte sedimentation rate after hip fractures

Ellitsgaard

Andersson

Jensen

et al. 1991

International Orthopaedics

View full text Add to dashboard Cite

Serial measurements of C-reactive protein (CRP) levels and erythrocyte sedimentation rates (ESR) were performed during the week after operation in 140 patients with hip fractures. There was no selection, and patients with minor or major complications before or after operation were included. In uncomplicated cases, the ESR was variably raised during the first week, whereas the CRP showed a distinct pattern with a rapid increase on the second day; it then decreased by the 7th day. In cases with early postoperative bronchopneumonia and deep wound infection, the CRP was high, but minor infections did not influence the usual levels. Complications had no effect on the ESR during the 1st week.

show abstract

“…Therefore, residual tumor cells might have affected the CRP level and impaired its specificity. 10 Recently, procalcitonin has been investigated as a biomarker for the diagnosis of bacterial infections. 11,12 Therefore, the serum CRP level in combination with procalcitonin level might be more suitable for predicting infectious events after HSCT.…”

Section: Discussionmentioning

confidence: 99%

Prediction of transplant-related complications by C-reactive protein levels before hematopoietic SCT

Sato

Nakasone

Oshima

et al. 2012

Bone Marrow Transplant

View full text Add to dashboard Cite

Various biomarkers have been investigated with regard to their ability to predict the outcome of allogeneic hematopoietic SCT (HSCT). In this study, we retrospectively reviewed 90 recipients who received HSCT between 2007 and 2011 in our institution, and evaluated the predictive value of the baseline serum C-reactive protein (CRP) levels just before the initiation of conditioning for transplant-related complications after allogeneic HSCT. A receiver-operating characteristic curve revealed that the baseline serum CRP levels had an excellent predictive value for non-relapse mortality (NRM), with an area under the curve of 0.83. The sensitivity and specificity for NRM were 80% and 87%, respectively, with a cutoff of 0.6 mg/dL. With this cutoff value, multivariate analyses revealed that a higher baseline CRP level was an independent risk factor for NRM (HR 6.21, Po0.01), grade III-IV acute GVHD (HR 3.91, P ¼ 0.03) and poor overall survival (HR 3.27, P ¼ 0.0018). On the other hand, the baseline CRP level did not predict infectious events. These findings suggested that CRP levels before conditioning may be a useful predictive biomarker for poor survival.

show abstract

Reevaluation of C-Reactive Protein in Cancer Sera by Radioimmunoassay and Radial Immunodiffusion

Cited by 22 publications

References 9 publications

Analyte Comigrating with Trisialotransferrin during Capillary Zone Electrophoresis of Sera from Patients with Cancer

Analyte Comigrating with Trisialotransferrin during Capillary Zone Electrophoresis of Sera from Patients with Cancer

Changes in C-reactive protein and erythrocyte sedimentation rate after hip fractures

Prediction of transplant-related complications by C-reactive protein levels before hematopoietic SCT

Contact Info

Product

Resources

About